PL444722A1 - Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym - Google Patents

Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym

Info

Publication number
PL444722A1
PL444722A1 PL444722A PL44472223A PL444722A1 PL 444722 A1 PL444722 A1 PL 444722A1 PL 444722 A PL444722 A PL 444722A PL 44472223 A PL44472223 A PL 44472223A PL 444722 A1 PL444722 A1 PL 444722A1
Authority
PL
Poland
Prior art keywords
liposome
cancer activity
drug delivery
drugs
weight
Prior art date
Application number
PL444722A
Other languages
English (en)
Inventor
Olga Święch
Agata KRZAK
Joanna PIETRAS
Weronika PIOTROWSKA
Anna Boguszewska-Czubara
Mateusz Psurski
Joanna Wietrzyk
Ewa OLISZEWSKA
Joanna JAROSZ
Wojciech Smoron
Renata Bilewicz
Original Assignee
Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością filed Critical Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL444722A priority Critical patent/PL444722A1/pl
Priority to PCT/PL2024/000024 priority patent/WO2024228633A1/en
Priority to CN202480044870.0A priority patent/CN121443273A/zh
Priority to IL324425A priority patent/IL324425A/en
Priority to EP24740621.8A priority patent/EP4704811A1/en
Publication of PL444722A1 publication Critical patent/PL444722A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest modyfikowany liposom do przenoszenia leków charakteryzujący się tym, że złożony jest z trzech głównych lipidów, to jest DPPC w ilości od 48,6% do 70,7% wagowych, cholesterolu w ilości od 18,3% do 18,6% wagowych, DSPE-PEG(2000)aminy w ilości od 10,6% do 10,7% wagowych oraz co najmniej jednego lipidu z grupy obejmującej DOPC i DOPG, przy czym zawartość DOPC w liposomie wynosi nie więcej niż 22,4% wagowych, a zawartość DOPG w liposomie wynosi nie więcej niż 22,6% wagowych. Kolejnymi przedmiotami zgłoszenia jest powyższy liposom do zastosowania do przenoszenia co najmniej jednego leku, zwłaszcza o działaniu antynowotworowym oraz sposób ładowania liposomu lekami zwłaszcza o działaniu antynowotworowym.
PL444722A 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym PL444722A1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL444722A PL444722A1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym
PCT/PL2024/000024 WO2024228633A1 (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity
CN202480044870.0A CN121443273A (zh) 2023-05-03 2024-05-03 用于递送药物的经修饰脂质体、脂质体用于递送药物特别是具有抗癌活性的药物的用途、以及将药物特别是具有抗癌活性的药物负载到脂质体的方法
IL324425A IL324425A (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anticancer activity, and methods of loading liposome with drugs, especially with anticancer activity
EP24740621.8A EP4704811A1 (en) 2023-05-03 2024-05-03 Modified liposome for drug delivery, use of liposome for drug delivery, especially with anti-cancer activity, and ways to load liposome with drugs, especially with anti-cancer activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL444722A PL444722A1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym

Publications (1)

Publication Number Publication Date
PL444722A1 true PL444722A1 (pl) 2024-11-04

Family

ID=91898578

Family Applications (1)

Application Number Title Priority Date Filing Date
PL444722A PL444722A1 (pl) 2023-05-03 2023-05-03 Modyfikowany liposom do przenoszenia leków, zastosowanie liposomu do przenoszenia leków, zwłaszcza o działaniu antynowotworowym oraz sposoby ładowania liposomu lekami, zwłaszcza o działaniu antynowotworowym

Country Status (5)

Country Link
EP (1) EP4704811A1 (pl)
CN (1) CN121443273A (pl)
IL (1) IL324425A (pl)
PL (1) PL444722A1 (pl)
WO (1) WO2024228633A1 (pl)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096139A1 (en) * 2015-12-03 2017-06-08 Boston Medical Center Corporation B cell-based cancer immunotherapy
EP3530266A1 (en) * 2018-02-27 2019-08-28 LipoCoat B.V. A lipid-based coating composition, and an object having a lipid-based coating
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) * 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
WO2013086526A1 (en) * 2011-12-09 2013-06-13 The Regents Of The University Of California Liposomal drug encapsulation
EP2968144A1 (en) * 2013-03-13 2016-01-20 Mallinckrodt LLC Liposome oxaliplatin compositions for cancer therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096139A1 (en) * 2015-12-03 2017-06-08 Boston Medical Center Corporation B cell-based cancer immunotherapy
EP3530266A1 (en) * 2018-02-27 2019-08-28 LipoCoat B.V. A lipid-based coating composition, and an object having a lipid-based coating
PL438742A1 (pl) * 2021-08-14 2023-02-20 Bs Biotechna Spółka Z Ograniczoną Odpowiedzialnością Liposom kationowy wiążący i stabilizujący RNA, jego zastosowanie i sposób ładowania liposomu emetyną

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEUNG CCL, AL-JAMAL WT: "Int J Pharm. 2019 Jul 20;566:687-696", STERICALLY STABILIZED LIPOSOMES PRODUCTION USING STAGGERED HERRINGBONE MICROMIXER: EFFECT OF LIPID COMPOSITION AND PEG-LIPID CONTENT, DOI: 10.1016/j.ijpharm.2019.06.033 *

Also Published As

Publication number Publication date
WO2024228633A1 (en) 2024-11-07
CN121443273A (zh) 2026-01-30
IL324425A (en) 2026-01-01
EP4704811A1 (en) 2026-03-11

Similar Documents

Publication Publication Date Title
De Blank et al. MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus
Raymond et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
Ceresoli et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
Clausen Quantification of Na+, K+ pumps and their transport rate in skeletal muscle: functional significance
Bonomi et al. Comparison of survival and quality of life in advanced non–small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
Bible et al. A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer
Oudard et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer
Moudgil et al. Hypoxic pulmonary vasoconstriction
Tapson et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial
Gelmon et al. Phase I study of liposomal vincristine
Georgoulias et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial
Berruti et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design
Rivera et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer
US8168216B2 (en) Treatment of triple receptor negative breast cancer
Rubin et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors
Braun et al. The effect of local anesthetic and corticosteroid combinations on chondrocyte viability
DeVore et al. Phase II study of irinotecan plus cisplatin in patients with advanced non–small-cell lung cancer
Pföhler et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study
Bell et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients
Yin et al. Glucose stimulates calcium-activated chloride secretion in small intestinal cells
Bolis et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial
Sparano et al. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study
Kuwahira et al. Splenic contraction-induced reversible increase in hemoglobin concentration in intermittent hypoxia
Ban et al. Efficacy and safety of palbociclib in heavily pretreated patients with HR+/HER2-metastatic breast cancer
Reni et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial